Cargando…
B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis
BACKGROUND: Rituximab (RTX) may favorably affect skin and lung fibrosis in patients with systemic sclerosis (SSc); however, the underlying molecular mechanisms remain unknown. We aimed to explore the hypothesis that RTX may mediate its antifibrotic effects by regulating the expression of Dickkopf-1...
Autores principales: | Daoussis, Dimitrios, Tsamandas, Athanassios, Antonopoulos, Ioannis, Filippopoulou, Alexandra, Papachristou, Dionysios J., Papachristou, Nicholaos I., Andonopoulos, Andrew P., Liossis, Stamatis-Nick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875588/ https://www.ncbi.nlm.nih.gov/pubmed/27208972 http://dx.doi.org/10.1186/s13075-016-1017-y |
Ejemplares similares
-
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin
por: Daoussis, Dimitrios, et al.
Publicado: (2012) -
B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence
por: Daoussis, Dimitrios, et al.
Publicado: (2011) -
Dkk1: A key molecule in joint remodelling and fibrosis
por: Klavdianou, Kalliopi, et al.
Publicado: (2017) -
DKK-1 Is Underexpressed in Mesenchymal Stem Cells from Patients with Ankylosing Spondylitis and Further Downregulated by IL-17
por: Daoussis, Dimitrios, et al.
Publicado: (2022) -
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
por: Daoussis, Dimitrios, et al.
Publicado: (2010)